Behind the Strategy: An Expert’s Perspective

Tonya Dowd, MPH, Executive Vice President, Reimbursement, Health Economics, Market Access and Corporate Development • February 23, 2026

Why PRIA?

Many people ask us, “Why PRIA? What do you offer that other consulting firms don’t?”


I’ve spent time reflecting on that question. It seems simple- but the answer goes deeper than reimbursement expertise, market access strategy, or regulatory experience alone.


The difference is this: we care- and we execute.


PRIA combines deep strategic insight with hands-on execution across reimbursement, regulatory, market access, patient access, and payer adoption. We don’t just develop recommendations; we stay to implement them, refine them, and see them through.



What Makes PRIA Different


1. We start with patients.
Access isn’t theoretical for us. We’ve helped 40,000+ patients gain access to innovative technologies that improve and extend their lives. That urgency shapes every engagement.


2. We think strategically and holistically.
We ask “
why” before “how,” ensuring reimbursement, regulatory, evidence strategy, pricing, and commercialization are aligned- not siloed.


3. We partner from concept through commercialization.
Ideally, we’re in the game from Spring Training through the ninth inning of the World Series, helping build the full strategy early. But when we’re brought in mid-game, we quickly assess the field, clarify the signals, and help load the bases for a win.


In reimbursement and market access, you need two-way players, strategy and execution. Think Babe Ruth meets Shohei Ohtani. We help define the game plan and step up to the plate when it’s time to deliver.


4. We execute- especially when things get hard.
Reimbursement is rarely linear. Policies shift. Claims deny. Coverage lags. The difference is that we don’t disappear when it gets messy.


As one client shared:


“We talked to a few reimbursement groups, but we wanted a partner who could do both strategy and execution- not just give recommendations. The execution piece, especially patient access support, was really important to us. We also needed a team with real experience in the reimbursement areas we play in and the ability to problem-solve when things aren’t straightforward. PRIA fit that better than anyone else we spoke with.”


And another client weighed in on our long-term commitment:


“They’ve stayed engaged the whole time. PRIA brings in the right people when we need them, they understand our goals, and they work alongside us until things are resolved, not just until a deliverable is sent. When reimbursement gets messy (and it does), they don’t disappear. They stick with it.”


PRIA is not a recommendation shop. We are a strategic and execution partner.

In today’s environment, reimbursement and market access are not downstream considerations- they are core drivers of valuation, acquisition potential, and long-term viability and should be developed in sync with your regulatory strategy.



Let’s Connect at LSI 2026


We’ll be attending LSI 2026 in Dana Point this March. If you’re building innovative technology and want to ensure your reimbursement strategy strengthens, rather than limits, your valuation story, we would welcome the opportunity to connect.


Let’s step onto the field early and build the right game plan.



Our team of reimbursement and market access experts are here to guide innovators navigating the path to commercial success- how can we help you?

Contact PRIA Healthcare to Learn More >>

Tonya Dowd, MPH


Executive Vice President,Reimbursement, Health Economics, Market Access & Corporate Development

Click the Icon below to share this with your network

The first in a series on the shifting landscape of patient access
By Chelsy Peet August 20, 2026
The first in a series on the shifting landscape of patient access, from inside the team that fights for the patient's first stamp on their passport.
RAPID and the Long Effort to Close Medicare's Coverage Gap by Tonya Dowd and Sam Murray
By Tonya Dowd & Sam Murray August 17, 2026
FDA authorization does not guarantee timely Medicare coverage. RAPID is CMS’s latest attempt to narrow that gap—and potentially one of its most consequential.
PRIA's webinar, How Payers Decide: Coverage, Evidence, and Value in MedTech Commercialization
July 28, 2026
PRIAs webinar, How Payers Decide: Coverage, Evidence, and Value in MedTech Commercialization featuring Dr. Julie Kessel and Dr. Dot Verbrugge
Stop Guessing What FDA Wants by Sam Murray
By Sam Murray June 4, 2026
Stop Guessing What FDA Wants
Regulatory Meets Reimbursement: What MedTech Innovators Need to Know About FDA Breakthrough & Beyond
June 3, 2026
Regulatory Meets Reimbursement: What MedTech Innovators Need to Know About FDA Breakthrough and Beyond
You Got Your 510(k). Now What?
By Suzy Engwall May 28, 2026
You Got Your 510(k). Now What?
Right Sizing Your Quality System by Sam Murray
By Sam Murray, Head of Regulatory & Quality May 21, 2026
Right Sizing Your Quality System
Cleared for takeoff: Insights from a Medtech First Officer
By Suzy Engwall May 19, 2026
Five Mistakes MedTech StartUps Make Before Their First VAC Meeting
Using Regulatory as a Strategy and Not a Milestone
By Sam Murray, PRIA May 14, 2026
Using Regulatory as a Strategy and Not a Milestone
Reading the Water: Navigating What Matters in Regulatory and Quality  - Sam Murray, PRIA
By Sam Murray, Head of Regulatory & Quality May 6, 2026
An informative article series from PRIA Healthcare's Head of Regulatory and Quality, Sam Murray
Medical device strategy CMS/FDA RAPID program
By Tonya Dowd & Sam Murray April 24, 2026
Examining the impact of the RAPID program, accelerating Medicare access for Breakthrough Devices by aligning FDA approval & CMS coverage, earlier.
MedTech Clinical Evidence Strategy
By PRIA Healthcare April 20, 2026
PRIA's experts on reimbursement and regulatory issues weigh in on CMS's proposed NTAP change, and what it may mean for MedTech innovations.